Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
about
Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusFludarabine in Waldenstrom's macroglobulinemia.New developments in the management of Waldenström macroglobulinemiaWaldenstrom macroglobulinemia: prognosis and management.Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosisHow to manage Waldenstrom's macroglobulinemia.Waldenström macroglobulinaemia: the key questions.Waldenström macroglobulinemia: from biology to treatment.Immunologic and clinical effects of targeting PD-1 in lung cancer.Current and future therapeutic approach for Waldenström's macroglobulinemia.Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies.Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia.Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia.Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma.Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance.Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.Lenalidomide is safe and active in Waldenström macroglobulinemia.Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia.Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database.Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma.The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.Waldenstrom's Macroglobulinemia: An Update.Effective treatment of Bing-Neel Syndrome with oral fludarabine: a case series of four consecutive patients.Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Guidelines on the diagnosis and management of Waldenström macroglobulinaemia.Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.Waldenström macroglobulinemia treatment algorithm 2018.Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent.A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone
P2860
Q33408517-E0297DFF-5BBC-4C57-9DEF-DFD5DFD643B0Q33414529-79661C3F-4E3E-4ADB-8354-5C309684750DQ33421444-296B97AD-FAC0-4172-B3B6-C0018F236798Q33434251-8BDC094C-AE70-4A04-BD12-154E9051055EQ33438490-79B5FE36-FB30-4881-87B3-5CCDFB8AF44AQ34106817-94D1FBA0-190B-406A-8A52-C3CAA385CCD2Q34351916-BF6A4D3C-E91A-479F-8EB5-00B3A2FE5CE1Q34553880-942DE998-5932-4F6E-A1B1-37DFCFE55020Q35244911-D59FB1F3-0E9F-4AD9-85E4-59BA434AC7BCQ35806665-01D3580E-DEC6-4BF6-B1D7-52DABDFFD9CAQ36764811-3AD23719-9DF3-4649-980F-78ACCEE9AC93Q38104808-9EA2A1B7-3F9E-422F-82D0-A651D67B8435Q38176969-17427DEF-CA5E-4C73-945A-5BD88D0A7C89Q38201196-8D11E69F-66D2-4BCB-92BF-6E86DCD6D3DEQ38206820-7FBF3C31-BE50-437F-BB76-A94EAF319B2FQ38574045-AC08FCD5-A906-4557-BB9D-6564C7B2B79DQ38582791-8D7A181C-069B-4E84-84A1-9FFC510463CAQ38644775-F016C572-45F0-4763-90C7-A52E7DF6F20BQ38645082-02D28747-C55B-4E58-9713-9D08D204BC27Q38693304-78E5E5A3-0B68-463B-9666-9B1188D2B83AQ38711166-9FDBECFA-D621-4BAC-8E07-765451E56FABQ38760522-BA442E1D-D29D-4CCA-ADF1-15FE884EF6AEQ38774535-82BFE7D4-68AA-4EB3-BD93-17875C7BF7B2Q38933428-39D7F82B-B06F-40D2-B35D-B57F925F5E59Q38970612-1670E810-8158-4988-9EE9-CF7847CA2560Q38973119-687F3776-A26A-42A9-AD4E-37729C8879A4Q39044362-D7955B7D-2878-45B2-956B-4D10B5FE2B34Q40651796-9A1F519E-EB77-40AF-80DE-358A27C5D660Q40773209-3E5EC768-D66E-43B7-96EA-F01CF089BFAAQ41252640-59FEF9C1-3427-4426-B69C-C2D57C75B9D2Q41496252-EA4CC62C-60EA-4FE5-BCA8-62B6DC6F918CQ42660670-5E34D77D-E034-4394-BA19-5373A63DF822Q47736653-D844D2BB-193B-4AB0-987F-F7159B49425BQ48191596-8C69667D-95CF-4E69-AD9C-76669AC5193EQ51199274-BBF5DFB6-EAC4-439A-9E6D-91899634DA6DQ52840250-3C5A89DD-07D8-4D29-9305-08A220FE6C8DQ52969991-773ED76C-97DA-49A8-9B70-6EDA8DEB8307Q55018872-1F05C883-6E68-404C-9597-873CFDC165AEQ55397597-E97EC34C-BA6C-45FC-9F2D-974AEAB258D0Q58415785-A5F24C71-11A4-4691-88E7-9378BEAC7FF2
P2860
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Results of a randomized trial ...... or lymphoplasmacytic lymphoma.
@en
Results of a randomized trial ...... or lymphoplasmacytic lymphoma.
@nl
type
label
Results of a randomized trial ...... or lymphoplasmacytic lymphoma.
@en
Results of a randomized trial ...... or lymphoplasmacytic lymphoma.
@nl
prefLabel
Results of a randomized trial ...... or lymphoplasmacytic lymphoma.
@en
Results of a randomized trial ...... or lymphoplasmacytic lymphoma.
@nl
P2093
P356
P1476
Results of a randomized trial ...... or lymphoplasmacytic lymphoma.
@en
P2093
Adrian Copplestone
Bruno Royer
Caroline Dartigeas
David Wright
John Francis Seymour
Julie Lejeune
Maeve Ewings
Marie-Sarah Dilhuydy
Marion Malphettes
P304
P356
10.1200/JCO.2012.44.7920
P407
P577
2012-12-10T00:00:00Z